Evotec publishes presentation for June 11, 2026 annual general meeting in Hamburg

• Evotec outlined a “Horizon” reset to simplify operations, lift utilization, monetize Just–Evotec Biologics, drive pipeline value, target profitable growth to 2030.
• Targets revenue above EUR 1 billion by 2030 with 8%-12% CAGR; targets EBITDA margin of 20% in 2028, above 20% in 2030.
• Reported 2025 external revenue of EUR 788.4 million; adjusted EBITDA of -EUR 12 million, with D&PD -EUR 12 million, JEB EUR 53.2 million.
• Planned restructuring includes cutting global sites to 10 from 14 within two years; plans to eliminate about 800 positions.
• Highlighted a shift at Just–Evotec Biologics toward a technology licensing model, citing USD 350 million upfront, USD 300 million of license revenue in 2026-2028.
• Shareholders will vote to discharge management board members for 2025; vote to discharge supervisory board members for 2025.
• Vote on appointing BDO as auditor for 2026 financial statements; vote on BDO as auditor for sustainability reporting for 2026.
• Vote on approving the 2025 remuneration report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.